Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  VBI Vaccines Inc.    VBIV   CA91822J1030

VBI VACCINES INC.

(VBIV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société VBI VACCINES INC.
03/12VBI VACCINES : Appoints Damian Braga to Board of Directors
BU
03/05VBI VACCINES : Provides Corporate Update, Outlook for 2020, and Year-End 2019 Fi..
BU
03/03VBI VACCINES : Provides Update on Part A of Ongoing Phase 1/2a Study Demonstrati..
BU
03/02VBI VACCINES : Announces Dosing of First Recurrent GBM Patient in Phase 2a Study..
BU
01/14VBI VACCINES : Regains Compliance with Nasdaq Minimum Bid Price Requirement
BU
01/09VBI VACCINES : Announces Second Pivotal Phase 3 Study of Sci-B-Vac® Meets Primar..
BU
2019VBI VACCINES : Presents Early GBM Tumor Response and Immunologic Data from Part ..
PU
2019VBI VACCINES : Presents Early GBM Tumor Response and Immunologic Data from Part ..
BU
2019VBI VACCINES : and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-..
BU
2019VBI VACCINES : to Present Initial Phase 1/2a Part B Data of VBI-1901 at the 2019..
BU
2019VBI VACCINES : Announces Third Quarter 2019 Financial Results and Provides Corpo..
BU
2019VBI VACCINES : to Present New Immuno-Oncology Data at the World Vaccine Congress..
BU
2019VBI VACCINES : Announces Late-Breaker Poster Presentation at The Liver Meeting® ..
BU
2019VBI VACCINES : Announces Late-Breaker Oral Presentation at IDWeek 2019™
BU
2019VBI VACCINES : Announces Closing of Public Offering of Common Stock and Full Exe..
BU
2019VBI VACCINES : Announces Pricing of $35 Million Public Offering
BU
2019VBI VACCINES : Announces Proposed Public Offering of Common Shares
BU
2019VBI VACCINES : Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine..
BU
2019VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Cor..
GL
2019VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ong..
GL
2019VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes
GL
2019VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions for Suc..
GL
2019VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phas..
GL
2019VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clini..
GL
2019VBI Vaccines Announces Results of Annual General Meeting
GL
2019VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-..
GL
2019VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Developm..
GL
2019VBI Vaccines Appoints Joanne Cordeiro to Board of Directors
GL
2019VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference
GL
2019VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 F..
GL
2018VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial..
GL
2018VBI Vaccines Announces Pricing of $37.5 Million Public Offering
GL
2018VBI Vaccines Announces Proposed Public Offering of Common Shares
GL
2018VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (..
GL
2018VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI..
GL
2018VBI Vaccines Responds to Unfounded Allegations in Globes Article
GL
2018VBI Vaccines to Present at the 20th Annual Rodman & Renshaw Global Investment..
GL
2018VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head..
GL
2018VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Cor..
GL
2018VBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference
GL
2018VBI Vaccines Announces Results of Annual General Meeting
GL
2018VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative C..
GL
2018VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical S..
GL
2018VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 i..
GL
2018VBI Vaccines Announces Changes to its Board of Directors
GL
2018VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Stu..
GL
2017VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® ..
GL
2017VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Suc..
GL
2017VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1..
GL
2017VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum
GL
2017VBI Vaccines Announces Closing of Public Offering and Concurrent Registered D..
GL
2017VBI Vaccines Announces Full Exercise of Underwriters' Option to Purchase Addi..
GL
2017VBI VACCINES : Hepatitis B Data Selected as Presidential Poster of Distinction a..
MW
2017VBI VACCINES : to Present at The World Vaccine Congress Europe 2017 in Barcelona
MW
Upcoming event on VBI VACCINES INC.